Tirzepatide, a dual GIP GLP 1 receptor co agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction Cardiovascular Diabetology Springer Nature Link Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Dose Chart [Cagrilintide] GLP 1 Forum Unveiling the Therapeutic Potential of the Second Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults GLP 1 Weight Loss Drugs: How Semaglutide & Tirzepatide Redefine Obesity Care